10-K/A: Immix Biopharma Amends 2025 Annual Report, Boosts Cash

Immix Biopharma, Inc. filed an amendment to its 2025 Annual Report on Form 10-K, primarily to correct the auditor report date, while revealing significant capital raises and increased liquidity despite growing net losses.

Summary

• Immix Biopharma, a clinical-stage biopharmaceutical company, filed an amendment to its 2025 Annual Report on Form 10-K, primarily to correct the date of the independent auditor's report.
• The company reported a net loss of $29.4 million for the year ended December 31, 2025, an increase from $21.7 million in 2024, contributing to an accumulated deficit of $104.5 million.
• Cash and cash equivalents significantly increased to $93.9 million as of December 31, 2025, from $17.7 million in 2024, largely due to successful equity financings.
• Total assets grew to $104.8 million in 2025 from $22.9 million in 2024, while total liabilities increased to $11.0 million from $9.7 million.
• Research and development expenses rose to $16.3 million in 2025 from $11.3 million in 2024, reflecting ongoing clinical activities.
• General and administrative expenses also increased to $13.7 million in 2025 from $11.4 million in 2024.
• The company completed multiple capital raises in 2025, including an At-The-Market (ATM) offering yielding $4.4 million, a private placement generating $9.3 million, and an underwritten public offering raising $93.7 million.
• Immix Biopharma was awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) in July 2024, receiving $2.8 million in 2025 and $1.9 million in 2024, with $3.4 million remaining.
• The Nexcella, Inc. subsidiary, Immix's cell therapy division, merged into the company in May 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative update. While the company significantly improved its liquidity through substantial capital raises, the underlying operational losses and cash burn increased, which is typical for a clinical-stage biopharma but still a negative trend in core performance.

Positives

• Cash and cash equivalents increased substantially to $93,928,566 as of December 31, 2025, from $17,681,954 in 2024.
• Successfully raised significant capital through multiple offerings in 2025, including $4,409,430 net proceeds from an ATM facility, $9,300,000 gross proceeds from a private placement, and $93,700,000 net proceeds from an underwritten public offering.
• Secured an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support clinical development of NXC-201 for AL Amyloidosis, with $2.8 million received in 2025.
• Management believes existing cash and the CIRM grant will fund operating expenses and capital expenditure requirements for at least the next 12 months from the filing date.
• Total stockholders' equity increased significantly to $93,796,170 in 2025 from $13,251,203 in 2024.

Negatives

• Reported a net loss of $29,438,613 for the year ended December 31, 2025, an increase from $21,698,363 in 2024.
• Accumulated deficit grew to $104,463,284 as of December 31, 2025, from $75,024,671 in 2024.
• Net cash used in operating activities increased to $23,930,304 in 2025 from $14,595,102 in 2024, indicating a higher cash burn rate.
• Research and development expenses increased to $16,258,598 in 2025 from $11,292,702 in 2024.
• General and administrative expenses increased to $13,697,817 in 2025 from $11,381,978 in 2024.
• Loss per common share increased to $(0.89) in 2025 from $(0.76) in 2024, reflecting increased losses and share dilution.
• Interest income decreased to $555,526 in 2025 from $1,017,354 in 2024.

Risks

• Operating in a dynamic and highly competitive biotechnology industry.
• Product candidates require significant additional research and development efforts, including extensive preclinical studies, clinical trials, and regulatory approval prior to commercialization.
• Dependence on key personnel, contract manufacturers, and contract research organizations.
• Need to obtain additional financing to fund operations, as current financial resources are insufficient to entirely fund all efforts.
• Uncertainty regarding the successful completion of research and development, obtaining and maintaining adequate intellectual property protection, receiving necessary regulatory approvals, or achieving commercial viability for any approved products.
• Potential material adverse impact if regulatory approval is denied, delayed, or cannot be maintained.
• Exposure to concentration of credit risk, as cash and cash equivalents balances at financial institutions may exceed federally insured limits.
• Net operating loss (NOL) and credit carryforwards may be subject to substantial annual limitation due to ownership changes under Internal Revenue Code Sections 382 and 383.
• Potential involvement in claims that arise during the ordinary course of business, which can be costly, time-consuming, and divert management's attention.

Future Outlook

Management expects to continue reporting negative cash flows from operations and net losses. However, existing cash and cash equivalents as of December 31, 2025, combined with expected disbursements from the CIRM grant, are believed to be sufficient to fund operating expenses and capital expenditure requirements for at least the next 12 months from the filing date. The company anticipates requiring additional funds to establish commercial-scale manufacturing and for marketing and distribution of any approved products.

Management Comments

• "Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report."
• "Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report."
• "The Annual Report on Form 10-K/A of the Company for the period ended December 31, 2025 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934."
• "The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated."

Industry Context

StockSavvy.ai notes that Immix Biopharma operates in the highly capital-intensive and competitive clinical-stage biopharmaceutical sector, characterized by significant research and development expenditures and a long pathway to commercialization. The company's focus on cell therapies for AL Amyloidosis and immune-mediated diseases aligns with a growing trend in precision medicine, but success is contingent on navigating complex clinical trials and regulatory hurdles, common challenges for companies in this space.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global industry benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• No material pending litigation to which the company is a party or to which its property is subject.

Related Party Transactions

• Gabriel Morris, the company's Chief Financial Officer and a Board member, is the sole member of Alwaysraise LLC, which has a Management Services Agreement with the company. His annual base salary was increased to $475,000, effective January 1, 2024.
• Robinhood II LP, whose general manager is Nancy Chang, received $104,210 in cash and 75,000 shares with a grant date fair value of $123,750 for marketing services in 2025.

Stakeholder Impact

• Shareholders experienced significant dilution from multiple equity offerings in 2025, but also saw a substantial increase in the company's cash position, providing a longer operational runway. Potential for future value creation is tied to successful clinical development and commercialization of product candidates.
• Employees benefited from stock-based compensation plans and salary increases for key executives, enhancing retention and motivation.
• Creditors face reduced immediate credit risk due to the company's improved liquidity position.
• Potential customers could benefit from the development of new cell therapies for AL Amyloidosis and immune-mediated diseases, should product candidates achieve regulatory approval and commercialization.

Next Steps

• Achieve patient enrollment milestones for the California Institute for Regenerative Medicine (CIRM) grant to receive remaining $3.4 million in funds.
• Initiate and complete Phase II and Phase III studies for cell therapy products under the Patent License Agreement with a U.S. medical research foundation, triggering potential milestone payments.
• File the definitive proxy statement for the 2026 annual meeting of stockholders within 120 days after December 31, 2025.
• Continue research, development, and clinical testing of product candidates.
• Establish commercial-scale manufacturing arrangements and provide for marketing and distribution of products that receive regulatory approval.

Key Dates

Recommendation

While Immix Biopharma has significantly bolstered its cash reserves through successful capital raises, providing a crucial runway for operations, the company continues to incur substantial net losses and increased cash burn from R&D. The long-term potential hinges on successful clinical trial outcomes and regulatory approvals for its cell therapy candidates, which remain highly uncertain. The current financial position provides stability, but the lack of near-term revenue and increasing operational costs suggest a 'hold' position, awaiting clearer clinical milestones and a path to profitability.

Keywords

Biopharmaceutical, Cell Therapy, AL Amyloidosis, NXC-201, SEC Filing, 10-K/A, Financial Results, Capital Raise, Clinical Stage, Research and Development, Liquidity, Stock Options, Warrants, CIRM Grant, Nexcella, Corporate Governance